Bevacizumab in recurrent WHO grades II–III glioma
PurposeThe management of recurrent WHO grades II–III (rGII–III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment.MethodsIn this retrospective study, the main inclusion criteria were as follows: adult patients with his...
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Frontiers Media S.A.
2023-07-01
|
| coleção: | Frontiers in Oncology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1212714/full |